DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical firm, announced that CEO Rick Pauls will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. Mr. Pauls is scheduled to speak at 2:40 p.m. ET on March 15, and will also be available for one-on-one investor meetings throughout the event. DiaMedica's lead candidate, DM199, is the first synthetic form of the KLK1 protein, aiming to treat acute ischemic stroke and chronic kidney disease. Investors can contact their Oppenheimer representative to arrange meetings.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33^rd Annual Healthcare Conference, which will take place March 13^th – 15^th, 2023.

Mr. Pauls is scheduled to present at 2:40 p.m. Eastern Time on Wednesday, March 15, 2023. In addition to the presentation, Mr. Pauls will be available for one-on-one investor meetings throughout the conference. Investors that are interested in arranging a meeting should contact their Oppenheimer representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005071/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will Rick Pauls present at the Oppenheimer 33rd Annual Healthcare Conference?

Rick Pauls will present on March 15, 2023, at 2:40 p.m. Eastern Time.

What is the focus of DiaMedica Therapeutics Inc.?

DiaMedica Therapeutics Inc. focuses on developing treatments for neurological disorders and kidney diseases.

What is DM199 by DiaMedica Therapeutics Inc.?

DM199 is a synthetic form of the KLK1 protein, intended for treating acute ischemic stroke and chronic kidney disease.

How can investors meet with DiaMedica's management during the conference?

Investors interested in one-on-one meetings should contact their Oppenheimer representative.

What are the dates for the Oppenheimer 33rd Annual Healthcare Conference?

The conference will take place from March 13 to March 15, 2023.